Suresh S. Ramalingam, MD

Articles

Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLC

September 28th 2019

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Ramalingam on the Activity of Osimertinib Combinations in NSCLC

September 6th 2019

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Ramalingam on the Use of Osimertinib in Clinical Trial and Real-World Settings

April 24th 2019

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the impact of osimertinib (Tagrisso) in both clinical trial and real-world settings.

Dr. Ramalingam on Avelumab Plus Lorlatinib in NSCLC

June 23rd 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the combination of avelumab (Bavencio) plus lorlatinib in patients with non–small cell lung cancer.

Dr. Ramalingam on Plasma EGFR Mutations as a Predictor of Response in NSCLC

June 9th 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses plasma EGFR mutations as a predictor of response to osimertinib (Tagrisso) in the AURA3 trial in non–small cell lung cancer.

Dr. Ramalingam on the Significance of the FLAURA Trial in NSCLC

April 16th 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the significance of the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non

Dr. Ramalingam on FLAURA Findings in EGFR-Mutant NSCLC

September 13th 2017

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Dr. Ramalingam on the Role of Osimertinib in EGFR T790M-Positive Advanced NSCLC

December 7th 2016

Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Ramalingam Discusses the Utility of Tecemotide in NSCLC

August 1st 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the utility of the vaccine tecemotide as treatment for non-small cell lung cancer.

Dr. Ramalingam on the Results of the Phase III REVEL Study in NSCLC

June 5th 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses the results of the phase III REVEL study in NSCLC.

Dr. Ramalingam on Hsp90 Inhibition With Ganetespib

July 18th 2013

Suresh S. Ramalingam, MD, from the Winship Cancer Institute of Emory University, discusses the role of heat shock proteins in normal cells and their potential role in treating cancer.

Dr. Ramalingam Reviews the GALAXY-1 Trial Results

June 3rd 2013

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.

Dr. Ramalingam Explores Cytotoxics in Lung Cancer

January 22nd 2013

Suresh S. Ramalingam, MD, from Emory University's Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

Adjuvant Therapy for Non-Small Cell Lung Cancer: Impact of Recent Clinical Trials on Community Practice

March 2nd 2011

Non-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.